Ravulizumab Shows Favorable Survival and Improves Clinical Markers in Children With HSCT ‐ TMA : Results of a Phase 3 Trial

Hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) is a rare, life-threatening complication that can lead to multiorgan failure and death. The ALXN1210-TMA-314 global, Phase 3, open-label, single-arm trial evaluated ravulizumab, a C5 inhibitor, for treatment of HSCT-TMA in children (NCT04557735). Eligible participants aged ≥ 28 days to < 18 years had HSCT-TMA within 12 months from HSCT, which persisted for ≥ 72 h despite initial management. Participants received weight-based ravulizumab plus best supportive care during the 26-week treatment period, followed by a 26-week follow-up period. The protocol-defined primary endpoint was complete TMA response during the treatment period. Key secondary endpoints included individual TMA response components (proteinuria, platelets, and lactate dehydrogenase/schistocytes), overall survival (OS), and safety. Of 41 enrolled participants (mean age, 7.6 years; 51.2% female), 28 (68.3%) completed treatment, and 24 (58.5%) completed the study. Through the treatment period, 7 (17.1%) participants achieved complete TMA response, and 22 (53.7%) achieved partial TMA response; 29 (70.7%) participants achieved improvement in ≥ 1 TMA response component. Estimated OS was 92.6% at Day 100, 87.2% at Week 26, and 73.4% at Week 52. During treatment, a low incidence of serious TEAEs was assessed by investigators as related to ravulizumab (3 participants, 7.3%); no new safety signals were identified. No meningococcal infections were reported. In this global Phase 3 trial in children with HSCT-TMA, ravulizumab treatment resulted in excellent OS and normalization of early laboratory markers of TMA in many patients. TRIAL REGISTRATION: NCT04557735.

Authors

Institutions

Publication Details

Journal
American Journal of Hematology
Published
2026-11-13
DOI
https://doi.org/10.1002/ajh.70545
Primary Topic
Complement system in diseases
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Ravulizumab Shows Favorable Survival and Improves Clinical Markers in Children With HSCT ‐ TMA : Results of a Phase 3 Trial

Eric Scott Bachman, David Bueno, Sarah A. Lawson, Franco Locatelli et al.
4 links
American Journal of Hematology
Complement system in diseases
article

Ravulizumab Shows Favorable Survival and Improves Clinical Markers in Children With HSCT ‐ TMA : Results of a Phase 3 Trial

Eric Scott Bachman, David Bueno, Sarah A. Lawson, Franco Locatelli, Jude Fry, Michelle Long Schoettler, Christopher C. Dvorak, Cory Williams, Hideki Sano, Sonali Chaudhury, Daiichiro Hasegawa, Hyoung Jin Kang, Cynthia Carrillo-Infante, Yoshiyuki Takahashi, Min Qin, Aviva Krauss
article en

Abstract

Hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) is a rare, life-threatening complication that can lead to multiorgan failure and death. The ALXN1210-TMA-314 global, Phase 3, open-label, single-arm trial evaluated ravulizumab, a C5 inhibitor, for treatment of HSCT-TMA in children (NCT04557735). Eligible participants aged ≥ 28 days to < 18 years had HSCT-TMA within 12 months from HSCT, which persisted for ≥ 72 h despite initial management. Participants received weight-based ravulizumab plus best supportive care during the 26-week treatment period, followed by a 26-week follow-up period. The protocol-defined primary endpoint was complete TMA response during the treatment period. Key secondary endpoints included individual TMA response components (proteinuria, platelets, and lactate dehydrogenase/schistocytes), overall survival (OS), and safety. Of 41 enrolled participants (mean age, 7.6 years; 51.2% female), 28 (68.3%) completed treatment, and 24 (58.5%) completed the study. Through the treatment period, 7 (17.1%) participants achieved complete TMA response, and 22 (53.7%) achieved partial TMA response; 29 (70.7%) participants achieved improvement in ≥ 1 TMA response component. Estimated OS was 92.6% at Day 100, 87.2% at Week 26, and 73.4% at Week 52. During treatment, a low incidence of serious TEAEs was assessed by investigators as related to ravulizumab (3 participants, 7.3%); no new safety signals were identified. No meningococcal infections were reported. In this global Phase 3 trial in children with HSCT-TMA, ravulizumab treatment resulted in excellent OS and normalization of early laboratory markers of TMA in many patients. TRIAL REGISTRATION: NCT04557735.

American Journal of Hematology
Università Cattolica del Sacro Cuore (IT), Northwestern University (US), National Health Service (GB), Lurie Children's Hospital (US), Seoul National University (KR), Emory University (US), University of California, San Francisco (US), Hospital Universitario La Paz (ES), Birmingham Children's Hospital (GB), Seoul National University Children's Hospital (KR), Schneider Children's Medical Center (IL), Bambino Gesù Children's Hospital (IT), Kobe Children's Hospital (JP), Alexion Pharmaceuticals (United States) (US), Fukushima Medical University Hospital (JP), Children's Healthcare of Atlanta (US), Nagoya University (JP)
AstraZeneca, Alexion Pharmaceuticals
Good health and well-being
Complement system in diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon